Alkermes plc - Ordinary Shares (ALKS): Price and Financial Metrics


Alkermes plc - Ordinary Shares (ALKS)

Today's Latest Price: $18.37 USD

0.14 (0.77%)

Updated Nov 24 4:00pm

Add ALKS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ALKS Stock Summary

  • ALKS's went public 29.37 years ago, making it older than 83.45% of listed US stocks we're tracking.
  • The price/operating cash flow metric for Alkermes plc is higher than 92.27% of stocks in our set with a positive cash flow.
  • In terms of volatility of its share price, ALKS is more volatile than just 16.51% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Alkermes plc, a group of peers worth examining would be PSNL, RIGL, EMKR, ATNX, and CYRN.
  • ALKS's SEC filings can be seen here. And to visit Alkermes plc's official web site, go to www.alkermes.com.

ALKS Stock Price Chart Interactive Chart >

Price chart for ALKS

ALKS Price/Volume Stats

Current price $18.37 52-week high $21.88
Prev. close $18.23 52-week low $11.98
Day low $18.15 Volume 675,200
Day high $18.50 Avg. volume 1,571,055
50-day MA $17.07 Dividend yield N/A
200-day MA $17.17 Market Cap 2.92B

Alkermes plc - Ordinary Shares (ALKS) Company Bio


Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 and is based in Dublin, Ireland.


ALKS Latest News Stream


Event/Time News Detail
Loading, please wait...

ALKS Latest Social Stream


Loading social stream, please wait...

View Full ALKS Social Stream

Latest ALKS News From Around the Web

Below are the latest news stories about Alkermes plc that investors may wish to consider to help them evaluate ALKS as an investment opportunity.

Drug Addiction Treatment Market Strategic Insights 2020 with analysis of Leading Players: Pfizer, Indivior, Novartis, Alkermes, Cipla, Mylan, Dr. Reddy's Laboratorie, etc.

The Global Drug Addiction Treatment Market research study takes a comprehensive approach towards studying the key trends influencing the growth of this sector. The report comprises data that offers an in-depth insight into the business sector. The research report focuses

OpenPR | September 30, 2020

Alkermes: Schizophrenia Drug Producer Taking Market Share, 5.5% 3-Month Upside

Graphic Source: Alkermes plc Introduction: What is Alkermes plc? Alkermes plc (ALKS) is a global biopharmaceutical company focused on developing and commercializing products related to schizophrenia, Bipolar I Disorder, Opioid/Alcohol Dependence, and recently Oncology. They are focused on unmet medical needs in major therapeutic areas and retain a diversified portfolio...

Gunner Laine Hardy on Seeking Alpha | September 28, 2020

Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new real-world outcomes research and clinical data related to its psychiatry portfolio at the Psych Congress 2020 Virtual Experience, held Sept. 10-13, 2020. The company presented six…

PR Newswire | September 14, 2020

Biotech leaders call for Covid-19 data transparency, FDA independence

The guidance was laid out in a letter signed by leaders of eight biotech companies — including Alnylam and Alkermes — and BIO's president.

STAT News | September 3, 2020

Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors

DUBLIN, Aug. 19, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-3, a new phase 2 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy on the tumor microenvironment of a variety of advanced, malignant solid tumors….

PR Newswire | August 19, 2020

Read More 'ALKS' Stories Here

ALKS Price Returns

1-mo 15.46%
3-mo 13.47%
6-mo 12.29%
1-year -13.14%
3-year -64.02%
5-year -75.70%
YTD -9.95%
2019 -30.87%
2018 -46.08%
2017 -1.53%
2016 -29.98%
2015 35.55%

Continue Researching ALKS

Want to see what other sources are saying about Alkermes plc's financials and stock price? Try the links below:

Alkermes plc (ALKS) Stock Price | Nasdaq
Alkermes plc (ALKS) Stock Quote, History and News - Yahoo Finance
Alkermes plc (ALKS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9726 seconds.